Skip to content
DraconiticResearch
Search Sources API
197,785 studies31 sourcesUpdated 59 min ago
Peer-reviewedCC BY 4.0Clinical Case Reports

Immune Checkpoint Inhibitor‐Induced Diabetic Ketoacidosis in a Patient With Pre‐Existing Type 2 Diabetes: A Case Report

  • Lingfen Zeng1
  • Jieming Sun2
  1. 1Department of Internal Medicine The Third People's Hospital of Baiyun District Guangzhou Guangdong China
  2. 2Department of Clinical Laboratory The Third People's Hospital of Baiyun District Guangzhou Guangdong China
Read full textPDFDOICite

Abstract

Immune checkpoint inhibitors (ICIs) may cause rare life‐threatening ICI‐associated diabetes mellitus. We report a 60‐year‐old Chinese male with pre‐existing type 2 diabetes who developed toripalimab‐induced diabetic ketoacidosis after 3 treatment cycles. He also had toripalimab‐related hyperthyroidism. Clinicians should closely monitor plasma glucose during and after ICI therapy.

Related

  1. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in an adolescent with type 2 diabetes.
    Natalie Segev, Ryan P Brady, Lawrence Dolan +1
    JCEM case reportsPeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismEurope PMC
  2. Rapid-onset type 1 diabetes mellitus and diabetic ketoacidosis : A case series of programmed cell death 1 inhibitor-associated endocrine toxicity in China : Four case reports
    Huihui Mao, Xuehui Jiang, Xiaowei Huang +3
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  3. When diabetic ketoacidosis becomes a neurological emergency: cerebral edema in a child with new-onset type 1 diabetes mellitus - a case report and narrative review
    Mateusz Okonek, Anna Paczkowska, Kinga Drzewińska +4
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC
  4. Comment on Lan et al. Reducing Diabetic Ketoacidosis in Pediatric Type 1 Diabetes: The Impact of Screening Programs and Early Disease-Modifying Treatment. J. Clin. Med. 2026, 15, 5865
    Ercan Yılmaz, Zeynep Yamancan Yılmaz
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  5. Favorable CGM metrics do not exclude SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: an educational case report with narrative review of literature
    Miyuki Iwamoto, Shuji Hidaka, Takamasa Iwamoto +1
    Endocrine JournalPeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismJ-STAGE

Cite

BibTeXRIS
BibTeX
@article{zeng2026immune,
  title = {{Immune Checkpoint Inhibitor‐Induced Diabetic Ketoacidosis in a Patient With Pre‐Existing Type 2 Diabetes: A Case Report}},
  author = {Lingfen Zeng and Jieming Sun},
  journal = {Clinical Case Reports},
  year = {2026},
  month = nov,
  doi = {10.1002/ccr3.73834},
  url = {https://doi.org/10.1002/ccr3.73834},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Immune Checkpoint Inhibitor‐Induced Diabetic Ketoacidosis in a Patient With Pre‐Existing Type 2 Diabetes: A Case Report
AU  - Lingfen Zeng
AU  - Jieming Sun
PY  - 2026
DA  - 2026/11/03
JO  - Clinical Case Reports
DO  - 10.1002/ccr3.73834
UR  - https://doi.org/10.1002/ccr3.73834
AB  - Immune checkpoint inhibitors (ICIs) may cause rare life‐threatening ICI‐associated diabetes mellitus. We report a 60‐year‐old Chinese male with pre‐existing type 2 diabetes who developed toripalimab‐induced diabetic ketoacidosis after 3 treatment cycles. He also had toripalimab‐related hyperthyroidism. Clinicians should closely monitor plasma glucose during and after ICI therapy.
SN  - 2050-0904
ER  -